CENTOGENE
THE RARE DISEASE COMPANY



CentoGenome®

SEE DIAGNOSTICS IN A NEW WAY

A comprehensive view into patients' genetic data with whole genome sequencing

Key benefits

- Highly effective diagnostic tool, delivering high diagnostic yields and solving up to 30 % of exome sequencing negative cases*
- Reliable detection of virtually all types of disease-causing genetic variants
- Shorter time to therapy by directly analyzing known and potentially disease-causing variants in one single test
- Lifelong reclassification of reported variants
- Option for reanalysis and reinterpretation at low cost in case of uncertain or negative results

Highest quality and competency in WGS interpretation

- Nearly complete and uniform coverage of the entire coding and non-coding regions of the genome
- Mitochondrial genome analysis included
- >99% of the genome covered at ≥10x
- Best-in-class conclusive clinical reports with clear actionable results, recommendations and follow up steps
- Powered by CentoMD® – CENTOGENE's extensive rare disease data repository, which guarantees the best diagnostic yields

Especially recommended for patients:

- With heterogeneous phenotypes
- With unclear or atypical clinical symptoms
- With a long list of prior differential diagnoses
- Who have exhausted other genetic testing options

Save valuable time by using our expertise to diagnose your patients

V3.5eng_October2020

Contact Details

Phone: +49 (0)381 80 113 - 416
Email: customer.support@centogene.com
www.centogene.com

CLIA #99D2049715

CAP ACCREDITED COLLEGE of AMERICAN PATHOLOGISTS

ISO 15189 CAP ACCREDITED COLLEGE of AMERICAN PATHOLOGISTS

*Data on file at CENTOGENE and published work (e.g., Bertoli-Avella *et al.* 2020, PMID: 2860008; Clark *et al.* 2018, PMID: 30002876; Farnaes *et al.* 2018, PMID: 29644095).